Dyne Therapeutics News

Dyne Therapeutics Analyst Ratings

BenzingaMay 6 07:54 ET

Oppenheimer Sticks to Their Buy Rating for Dyne Therapeutics (DYN)

TipRanksMay 6 07:47 ET

Robust Financial Health and Promising Clinical Trials Bolster Buy Rating for Dyne Therapeutics

TipRanksMay 5 22:35 ET

Dyne Therapeutics Analyst Ratings

BenzingaMay 3 15:45 ET

Optimistic Buy Rating for Dyne Therapeutics Backed by Promising DYNE-101 Drug Efficacy Data

TipRanksMay 3 06:26 ET

Dyne Therapeutics Analyst Ratings

BenzingaApr 30 05:16 ET

Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Dyne Therapeutics (DYN) and Dexcom (DXCM)

TipRanksApr 30 05:01 ET

Dyne Therapeutics Analyst Ratings

BenzingaMar 26 10:06 ET

Analysts Are Bullish on Top Healthcare Stocks: Dyne Therapeutics (DYN), Addus Homecare (ADUS)

TipRanksMar 26 08:00 ET

Buy Rating Affirmed for Dyne Therapeutics: Promising Clinical Data and Solid Financial Position Fuel Optimism

TipRanksMar 7 23:25 ET

Dyne Therapeutics Analyst Ratings

BenzingaMar 7 11:17 ET

Buy Rating Affirmed for Dyne Therapeutics Amidst Promising Drug Data and Strategic Market Positioning

TipRanksMar 6 11:45 ET

Dyne Therapeutics Analyst Ratings

BenzingaMar 6 09:26 ET

Piper Sandler Keeps Their Buy Rating on Dyne Therapeutics (DYN)

TipRanksMar 6 07:36 ET

Dyne Therapeutics Analyst Ratings

BenzingaFeb 20 08:01 ET

H.C. Wainwright Initiates Dyne Therapeutics With Buy on Strong Outlook

InvestingFeb 20 06:26 ET

Stifel Nicolaus Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)

TipRanksFeb 9 08:29 ET

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Silence Therapeutics (SLN) and Dyne Therapeutics (DYN)

TipRanksJan 31 01:00 ET

Piper Sandler Keeps Their Buy Rating on Dyne Therapeutics (DYN)

TipRanksJan 8 07:37 ET

Raymond James Maintains Strong Buy on Dyne Therapeutics, Raises Price Target to $56

BenzingaJan 4 04:30 ET